Rheinische Friedrich-wilhelms-universitat Bonn

Crozet Medical Gmbh

Christa Muller

Evi Kostenis

Rhalid Akkari

Younis Baqi

Kirsten Ritter

Andreas Spinrath

Stephanie Hennen

Lucas Peters

Ali El-Tayeb

Jurgen Schrader

Jamshed Iqbal

A phosphorylated Areceptor agonist providing agonist properties on the Areceptor after dephosphorylation the phosphorylated Areceptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5'-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e.g. inflammatory events. In particular, compounds of formula (I) are also disclosed. 

Phosphorylated A2A receptor agonists

The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.

GPR 17 agonists and screening assay

Methods of identifying modulators of GPR17

Growing community of inventors

Bonn, Germany

Christa Muller